Multiple Myeloma and Amyloidosis Program, Cedars-Sinai
The Multiple Myeloma and Amyloidosis program provides a valuable resource to patients with these conditions. They offer a comprehensive array of services and treatment options based on the specific challenges of each patient’s disease characteristics and stage.
Through their various clinical trials, patients with multiple myeloma can access leading-edge, novel therapeutics. The clinical trials are complemented by the program’s basic and translational research in several promising areas, including anti-angiogenesis, vaccines, anti-virus treatments, gene therapy and third-generation bisphosphonates.
Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. With pioneering medical research achievements, education programs defining the future of healthcare, and wide-ranging community benefit activities, they’re setting new standards for quality and innovation in patient care.
The team includes healthcare professionals in the following areas:
